Longevity & AgingOral Peptide Sustains Ulcerative Colitis Improvements Through 76 Weeks
An oral drug called icotrokinra showed lasting benefits for adults with moderately to severely active ulcerative colitis, a disease that causes inflammation in the colon. In an initial randomized trial, 55% to 63% of patients receiving the drug improved by week 12, compared with 27% receiving placebo. Among patients who remained on treatment through week 76, approximately 56% to 59% were in remission, and examinations showed reduced inflammation in many participants. The drug blocks a receptor involved in inflammation and could eventually offer an alternative to injected treatments. However, the long-term findings describe patients continuing treatment, which can make results look better if nonresponders leave. The supplied article also lacks detailed safety results and dropout information. These promising findings do not establish long-term safety or approval for ulcerative colitis.
